DK1074542T3 - Sulfonamidholdige indolforbindelser - Google Patents

Sulfonamidholdige indolforbindelser

Info

Publication number
DK1074542T3
DK1074542T3 DK00905321T DK00905321T DK1074542T3 DK 1074542 T3 DK1074542 T3 DK 1074542T3 DK 00905321 T DK00905321 T DK 00905321T DK 00905321 T DK00905321 T DK 00905321T DK 1074542 T3 DK1074542 T3 DK 1074542T3
Authority
DK
Denmark
Prior art keywords
hydrogen
ring
represents hydrogen
indole compounds
cyanophenyl
Prior art date
Application number
DK00905321T
Other languages
English (en)
Inventor
Toru Haneda
Akihiko Tsuruoka
Junichi Kamata
Kazumasa Nara
Norihiro Ueda
Toshiaki Wakabayashi
Taro Semba
Naoko Hata
Yuji Yamamoto
Yoichi Ozawa
Naoko Tsukahara
Takashi Owa
Tadashi Okabe
Keiko Takahashi
Shinichi Hamaoka
Yasuhiro Funahashi
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Application granted granted Critical
Publication of DK1074542T3 publication Critical patent/DK1074542T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK00905321T 1999-02-26 2000-02-24 Sulfonamidholdige indolforbindelser DK1074542T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11049870A JP2000247949A (ja) 1999-02-26 1999-02-26 スルホンアミド含有インドール化合物

Publications (1)

Publication Number Publication Date
DK1074542T3 true DK1074542T3 (da) 2006-08-14

Family

ID=12843091

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00905321T DK1074542T3 (da) 1999-02-26 2000-02-24 Sulfonamidholdige indolforbindelser

Country Status (17)

Country Link
US (3) US6469043B1 (da)
EP (1) EP1074542B1 (da)
JP (3) JP2000247949A (da)
KR (1) KR100627611B1 (da)
CN (1) CN1132814C (da)
AT (1) ATE325094T1 (da)
AU (1) AU766936B2 (da)
CA (1) CA2327253C (da)
DE (1) DE60027648T2 (da)
DK (1) DK1074542T3 (da)
ES (1) ES2259997T3 (da)
HU (1) HU228787B1 (da)
NO (1) NO317299B1 (da)
NZ (1) NZ507464A (da)
PT (1) PT1074542E (da)
RU (1) RU2208607C2 (da)
WO (1) WO2000050395A1 (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02007249A (es) * 2000-02-03 2002-12-09 Eisai Co Ltd Inhibidor de la expresion de integrina.
JP2004508303A (ja) * 2000-08-30 2004-03-18 プライムサイト，インコーポレイティド 抗腫瘍療法
TWI283575B (en) * 2000-10-31 2007-07-11 Eisai Co Ltd Medicinal compositions for concomitant use as anticancer agent
ATE412895T1 (de) 2001-02-21 2008-11-15 Eisai R&D Man Co Ltd Verfahren zur untersuchung der wirkung eines angiogenese-hemmers unter vermittlung durch hemmung der integrin-expression
TWI325317B (en) * 2001-09-05 2010-06-01 Eisai R&D Man Co Ltd Appetite-stimulating agents and remedies for anorexia
US20040235866A1 (en) * 2001-09-05 2004-11-25 Takahisa Hanada Lymphocytic activation inhibitor and remedial agent for autoimmune disease
JP4542783B2 (ja) * 2002-03-05 2010-09-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド含有複素環化合物及び血管新生抑制剤とを組み合わせてなる抗腫瘍剤
CA2485725A1 (en) * 2002-06-05 2003-12-18 F. Hoffmann-La Roche Ag 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders
US7943800B2 (en) 2003-03-28 2011-05-17 Sloan-Kettering Institute For Cancer Research Migrastatin analogs and uses thereof
WO2004091664A1 (ja) * 2003-04-18 2004-10-28 Eisai Co., Ltd. 細胞質リンゴ酸脱水素酵素阻害剤
WO2005026118A1 (ja) * 2003-09-10 2005-03-24 Eisai Co., Ltd. スルホンアミド含有インドール化合物の結晶およびその製造方法
WO2005026119A1 (ja) * 2003-09-10 2005-03-24 Eisai Co., Ltd. スルホンアミド含有インドール化合物の製造方法
WO2005048938A2 (en) * 2003-11-13 2005-06-02 California Pacific Medical Center Anti-pecam therapy for metastasis suppression
JP5149001B2 (ja) * 2004-05-25 2013-02-20 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ 癌の処置におけるマイグラスタチンアナログ
WO2006030947A1 (ja) 2004-09-13 2006-03-23 Eisai R & D Management Co., Ltd. スルホンアミド含有化合物の血管新生阻害物質との併用
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
US8188141B2 (en) * 2004-09-23 2012-05-29 Sloan-Kettering Institute For Cancer Research Isomigrastatin analogs in the treatment of cancer
SI1859793T1 (sl) 2005-02-28 2011-08-31 Eisai R&D Man Co Ltd Nova kombinirana uporaba sulfonamidne spojine za zdravljenje raka
US8957070B2 (en) 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
CA2621181C (en) * 2005-08-30 2011-04-19 Asahi Kasei Pharma Corporation 5-isoquinolinesulfonamide compounds
JP5460054B2 (ja) * 2005-11-23 2014-04-02 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 腫瘍形成性ｒａｓ特異的細胞障害性化合物およびその使用法
US7625896B2 (en) * 2005-11-25 2009-12-01 Hoffman-La Roche Inc. Pyridylsulfonamide derivatives
WO2007086605A1 (ja) * 2006-01-27 2007-08-02 Eisai R & D Management Co., Ltd. スルホンアミド化合物の効果を予測する方法
US20100291592A1 (en) 2006-04-20 2010-11-18 Taro Semba Novel marker for sensitivity against sulfonamide compound
DE102007012284A1 (de) * 2007-03-16 2008-09-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007035333A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007035334A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007042154A1 (de) 2007-09-05 2009-03-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Arylsulfonylaminomethyphosphonsäure-Derivate, deren Herstellung und deren Verwendung als Arzneimittel
US20090142832A1 (en) * 2007-11-29 2009-06-04 James Dalton Indoles, Derivatives, and Analogs Thereof and Uses Therefor
JP2012136435A (ja) * 2009-03-30 2012-07-19 Eisai R & D Management Co Ltd 腫瘍組織の感受性を検査する方法
JP6302846B2 (ja) 2012-02-22 2018-03-28 サンフォード−バーンハム メディカル リサーチ インスティテュート Ｔｎａｐ阻害剤としてのスルホンアミド化合物およびその使用
CN104098498A (zh) * 2014-07-30 2014-10-15 天津市斯芬克司药物研发有限公司 一种吲唑类化合物及其制备方法
CA3082972C (en) * 2017-11-27 2022-10-11 Council Of Scientific & Industrial Research Indole (sulfomyl) n-hydroxy benzamide derivatives as selective hdac inhibitors
US11807606B2 (en) 2018-01-25 2023-11-07 Dana-Farber Cancer Institute, Inc. Sulfonamide derivatives for protein degradation
EP3953331B1 (en) * 2019-04-10 2024-11-20 Peloton Therapeutics, Inc. Pyrazolesulfonamides as antitumor agents
IL318189A (en) * 2022-08-15 2025-03-01 Recursion Pharmaceuticals Inc RBM39 heterocyclic modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9115160D0 (en) * 1991-07-12 1991-08-28 Erba Carlo Spa Methylen-oxindole derivatives and process for their preparation
US5169860A (en) * 1992-03-13 1992-12-08 Eli Lilly And Company Antitumor compositions and methods of treatment
ZA941500B (en) * 1993-03-10 1995-09-04 Lilly Co Eli Antitumor compositions and methods of treatment
WO1995007276A1 (en) * 1993-09-10 1995-03-16 Eisai Co., Ltd. Bicyclic heterocyclic sulfonamide and sulfonic ester derivatives
JP3545461B2 (ja) * 1993-09-10 2004-07-21 エーザイ株式会社 二環式ヘテロ環含有スルホンアミド誘導体
JP3690831B2 (ja) * 1995-02-27 2005-08-31 エーザイ株式会社 インドール含有スルホンアミド誘導体
KR100466955B1 (ko) * 1996-02-26 2005-06-10 에자이 가부시키가이샤 항종양제함유조성물
JP3868534B2 (ja) 1996-05-24 2007-01-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド誘導体の製造法および中間体
MXPA02007249A (es) * 2000-02-03 2002-12-09 Eisai Co Ltd Inhibidor de la expresion de integrina.

Also Published As

Publication number Publication date
JP2010180229A (ja) 2010-08-19
US6673787B2 (en) 2004-01-06
EP1074542B1 (en) 2006-05-03
US6469043B1 (en) 2002-10-22
NO20005357L (no) 2000-12-22
CN1294579A (zh) 2001-05-09
ES2259997T3 (es) 2006-11-01
KR100627611B1 (ko) 2006-09-25
HUP0101434A3 (en) 2001-10-29
CA2327253C (en) 2007-10-16
DE60027648T2 (de) 2007-04-05
EP1074542A4 (en) 2002-02-06
NO317299B1 (no) 2004-10-04
JP2000247949A (ja) 2000-09-12
KR20010042434A (ko) 2001-05-25
AU766936B2 (en) 2003-10-23
DE60027648D1 (de) 2006-06-08
ATE325094T1 (de) 2006-06-15
RU2208607C2 (ru) 2003-07-20
AU2691600A (en) 2000-09-14
CA2327253A1 (en) 2000-08-31
US20020128483A1 (en) 2002-09-12
HU228787B1 (en) 2013-05-28
HUP0101434A2 (hu) 2001-09-28
NO20005357D0 (no) 2000-10-24
PT1074542E (pt) 2006-07-31
JP3866041B2 (ja) 2007-01-10
WO2000050395A1 (en) 2000-08-31
EP1074542A1 (en) 2001-02-07
NZ507464A (en) 2003-10-31
US20020128480A1 (en) 2002-09-12
CN1132814C (zh) 2003-12-31
US6638964B2 (en) 2003-10-28

Similar Documents

Publication Publication Date Title
DK1074542T3 (da) Sulfonamidholdige indolforbindelser
NZ514873A (en) 4,5,6,7-tetrahydroindazole derivatives as antitumor agents
ATE129714T1 (de) Heterocyclische biphosphonsäurederivate.
NZ336302A (en) Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia
DK0749424T3 (da) Naphthalenderivater som prostaglandin-I2-agonister
DK0928788T3 (da) Imidazolidin-4-on-derivater, der er nyttige som anticancer-midler
ATE194610T1 (de) Derivate des radicicols
NO934536D0 (no) Fenoksy- og fenoksyalkyl-pepiridiner som antivirale midler
EP1110961A4 (en) Oxygenic heterocyclic compounds
CA2134077A1 (en) 4-imidomethyl-1-[2'phenyl-2'oxoethyl-]piperidines as serotonin 5ht2-antagonists, their preparation and use in therapy
ATE233242T1 (de) Chinoline und chinazoline verbindungen und ihre therapeutische anwendung
NZ221699A (en) Pyridazinone derivatives; pharmaceutical compositions and intermediates
TR200002831A2 (tr) Kinolin-4-İl türevleri I
NO961797L (no) Anvendelse av benzopyranderivater for fremstilling av farmasöytiske sammensetninger beregnet for behandling av patologier forbundet med den Na+-uavhengige C1-HCO3-utbytter
MEP12408A (en) Acyloxypyrrolidine derivatives and use thereof as ligands of v1b or both v1b and v1a receptors
HUP9902270A1 (hu) Analgetikus hatású akridinszármazékok, előállításuk és alkalmazásuk
EP0254527A3 (en) New tetracyclic indole derivatives
ES2182775T3 (es) Derivados de ciclohexano 1,4-disustituidos para el tratamiento de la depresion.
ECSP993005A (es) Compuestos de sulfonilbenceno como agentes anti-inflamatorios / analgesicos